Navigation Links
Sinovac Selected by Beijing CDC to Supply Hepatitis A Vaccine Healive(R)
Date:6/1/2010

BEIJING, June 1 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today that it has received the confirmation from the China International Tendering Company that Sinovac was selected by the Beijing Centers for Diseases Control and Prevention (Beijing CDC) to supply the Company's hepatitis A vaccine, Healive, to the Beijing Expanded Program of Immunization (EPI).

As part of the bidding process, the Beijing CDC evaluates potential suppliers and assigns scores for different factors, including product quality, service and price. Based on the comprehensive score, Sinovac was selected one of the two suppliers and was allocated a greater share of the total purchase order. The total ordered quantity allocated to Sinovac is approximately 477,000 doses.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "We are very pleased to have been awarded the purchase order for our hepatitis A vaccine by the Beijing Government, as it is a testament to our core competencies as a high quality domestic vaccine manufacturer. We will leverage our manufacturing capacity and established quality controls to produce the doses pursuant to the purchase order."

In February 2008, the Chinese government included hepatitis A vaccine into its national immunization program, and announced plans to expand vaccination to newborns nationwide by the end of 2010. The EPI program covers children at 18 months of age. The purchase plan from the Beijing CDC reflects the continued expansion of government purchase programs for vaccines as it is part of the national expanded immunization program (EPI) funded by Chinese government.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines. Its 30%-owned joint venture, Sinovac Dalian, focuses on the research, development, manufacturing and commercialization of vaccines, such as rabies, chickenpox, mumps and rubella vaccines for human use.

    For more information, please contact:

    Sinovac Biotech Ltd.:
     Chris Lee
     Tel:   +86-10-8279-9659
     Fax:   +86-10-6296-6910
     Email: info@sinovac.com

    Investors:
     Amy Glynn/Stephanie Carrington
     The Ruth Group
     Tel:   +1-646-536-7023/7017
     Email: aglynn@theruthgroup.com
            scarrington@theruthgroup.com

    Media:
     Jason Rando
     The Ruth Group
     Tel:   +1-646-536-7025
     Email: jrando@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sinovac Announces Plan to Launch Offering of Common Shares
2. Sinovac Announces Recent Developments
3. Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
4. Sinovac Named One of Chinas Top 10 Most Competitive Companies Listed Overseas in 2009
5. Sinovacs CEO Weidong Yin Nominated for China Central Televisions Prestigious Economic Man-of-the-Year Award
6. Sinovac Obtains Fourth H1N1 Vaccine Order from Chinese Central Government
7. Sinovac Files Shelf Registration Statement
8. Sinovacs PANFLU.1 (H1N1) Regulatory Approval Expanded to Include Geriatric Population
9. Sinovac Receives Purchase Order from Shanghai Government to Supply Hepatitis A Vaccine Healive(R)
10. Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine
11. Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... 2017  Xyntek Inc. has announced another milestone in their continued growth and ... meet the growing demands of customer engagements regionally.  ... Xyntek's new Midwest office is located at 318 West Adams Street, Suite 1528, ... Xyntek's recently ... ...
(Date:9/1/2017)... 1, 2017 Michael Penna , President ... highlights opportunities for growth in his response to the ... Equity is seeking a buyer for eMDs. Penna,s company, ... healthcare solutions Value Added Reseller and national leader in ... "As the healthcare market continues to dictate ...
(Date:8/29/2017)... LLC, the leading provider of continuous monitoring devices for the early ... Innovative Technology contract from Vizient, Inc., the largest member-driven health care ... ... of peripheral IV infiltration and extravasation events ... The Innovative Technology contract was awarded to ivWatch based on recommendations ...
Breaking Medicine Technology:
(Date:9/25/2017)... TX (PRWEB) , ... September 25, 2017 , ... Tim ... strengthen and enrich the communities it serves. By working closely with nonprofit groups and ... the formation of 60-day campaigns which aid worthy organizations, families and individuals. , ...
(Date:9/25/2017)... ... 25, 2017 , ... NCPDP Foundation , a 501(c)(3) ... awarded a $40,000 grant to Johns Hopkins Medicine to address patient safety risk ... to electronically cancel a prescription already submitted to a pharmacy. Studies indicate that ...
(Date:9/25/2017)... ... September 25, 2017 , ... Bobbie Horowitz was hardly able to ... health issues. As a cabaret and theater producer, Horowitz would manage to get to ... transportation in New York City, so she had to take a cab everywhere. ...
(Date:9/25/2017)... ... September 25, 2017 , ... Physician Partners of America announces that Chad ... Street as an interventional pain management specialist. , Dr. Gorman is a board-certified ... from private practice In Brooksville, Fla. His orthopedic background puts him in a unique ...
(Date:9/25/2017)... ... 2017 , ... Dr. Edward Hebert is celebrating his 33rd anniversary ... else,” said Dr. Hebert. “I count my blessings daily for the opportunity that the ... is what I look forward to the most. The relationships I have with my ...
Breaking Medicine News(10 mins):